Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress (ECC 2013)

27 Sep 2013
Amsterdam RAI, Amsterdam, Netherlands
Maximizing survival in metastatic castration-resistant prostate cancer (mCRPC)
Dr John Fitzpatrick - Irish Cancer Society & University College Dublin, Dublin, ...
Maximizing survival in metastatic castration-resistant prostate cancer (mCRPC) ( Dr John Fitzpatrick - Irish Cancer Society & University College Dublin, Dublin, Ireland )
10 Jan 2014
mCRPC: Challenges and opportunities in a booming area
Dr Nicolas Mottet - University Hospital, Saint-Étienne, France
mCRPC: Challenges and opportunities in a booming area ( Dr Nicolas Mottet - University Hospital, Saint-Étienne, France )
10 Jan 2014
Understanding the biology of the disease to guide treatment choices
Dr John Fitzpatrick - Irish Cancer Society & University College Dublin, Ireland
Understanding the biology of the disease to guide treatment choices ( Dr John Fitzpatrick - Irish Cancer Society & University College Dublin, Ireland )
10 Jan 2014
Predictors of response to mCRPC therapy: where do we stand?
Dr Ronald de Wit - Rotterdam Cancer Institute, Daniel den Hoed Cancer Center, Ne...
Predictors of response to mCRPC therapy: where do we stand? ( Dr Ronald de Wit - Rotterdam Cancer Institute, Daniel den Hoed Cancer Center, Netherlands )
10 Jan 2014
Managing mCRPC in daily practice: a pragmatic approach
Dr Alison Birtle - Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK
Managing mCRPC in daily practice: a pragmatic approach ( Dr Alison Birtle - Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK )
10 Jan 2014
Maximizing survival in metastatic Castration-Resistant Prostate Cancer: panel di...
J.M. Fitzpatrick, N. Mottet, R. de Wit, Rotterdam and A Birtle
Maximizing survival in metastatic Castration-Resistant Prostate Cancer: panel discussion ( J.M. Fitzpatrick, N. Mottet, R. de Wit, Rotterdam and A Birtle )
10 Jan 2014
Immuno-Oncology: the next new paradigm in cancer treatment? Chairman's welcome a...
Prof. Winald Gerritsen - Radboud University Nijmegen Medical Centre, The Netherl...
Immuno-Oncology: the next new paradigm in cancer treatment? Chairman's welcome and introduction ( Prof. Winald Gerritsen - Radboud University Nijmegen Medical Centre, The Netherlands )
3 Dec 2013
Cancer cells and the immune system: a natural story?
Prof. Laurence Zitvogel - INSERM, Institut Gustave Roussy, Villejuif, France
Cancer cells and the immune system: a natural story? ( Prof. Laurence Zitvogel - INSERM, Institut Gustave Roussy, Villejuif, France )
3 Dec 2013
Why are Immuno-Oncology compounds different?
Prof. Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain
Why are Immuno-Oncology compounds different? ( Prof. Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )
3 Dec 2013
Immuno-Oncology: a concept or already a reality?
Prof. Peter Johnson - Cancer Research UK Centre, University of Southampton, UK
Immuno-Oncology: a concept or already a reality? ( Prof. Peter Johnson - Cancer Research UK Centre, University of Southampton, UK )
3 Dec 2013
Chemosaturation therapy for cancers in the liver
Dr Stephen Fenwick - Aintree University Hospital, Liverpool, UK
Chemosaturation therapy for cancers in the liver ( Dr Stephen Fenwick - Aintree University Hospital, Liverpool, UK )
11 Nov 2013
Choosing the right treatment for each patient: The emergence of personalised hea...
Dr Frances Shepherd - Princess Margaret Hospital and the University of Toronto, ...
Choosing the right treatment for each patient: The emergence of personalised healthcare in non-small cell lung cancer ( Dr Frances Shepherd - Princess Margaret Hospital and the University of Toronto, Canada )
8 Nov 2013
The role of molecular pathways in therapeutic response and outcomes in breast ca...
Dr Fabrice André - Institut Gustave Roussy, Villejuif, France
The role of molecular pathways in therapeutic response and outcomes in breast cancer ( Dr Fabrice André - Institut Gustave Roussy, Villejuif, France )
8 Nov 2013
Traditional and personalised models of therapy in gastrointestinal and endocrine...
Dr Jaume Capdevila - Vall d'Hebron University Hospita, Barcelona, Spain
Traditional and personalised models of therapy in gastrointestinal and endocrine tumours: the role of histological and clinical markers ( Dr Jaume Capdevila - Vall d'Hebron University Hospita, Barcelona, Spain )
8 Nov 2013
Future perspectives: realising the potential of personalised healthcare in gynae...
Dr Jonathan Ledermann - University College London, United Kingdom
Future perspectives: realising the potential of personalised healthcare in gynaecological cancer ( Dr Jonathan Ledermann - University College London, United Kingdom )
8 Nov 2013
The revolution in personalised healthcare: Towards improved outcomes in oncology...
Dr Frances Shepherd - Princess Margaret Hospital and the University of Toronto, ...
The revolution in personalised healthcare: Towards improved outcomes in oncology: Conclusion and Summary ( Dr Frances Shepherd - Princess Margaret Hospital and the University of Toronto, Canada )
8 Nov 2013
Radium-223: A breakthrough in treatment for advanced prostate cancer?
Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK
Radium-223: A breakthrough in treatment for advanced prostate cancer? ( Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK )
1 Nov 2013
Genomic test to guide breast cancer treatment decisions approved in UK
Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK
Genomic test to guide breast cancer treatment decisions approved in UK ( Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK )
31 Oct 2013
What does NICE approval for Oncotype Dx in breast cancer mean?
Prof Justin Stebbing - Imperial College London, UK
What does NICE approval for Oncotype Dx in breast cancer mean? ( Prof Justin Stebbing - Imperial College London, UK )
31 Oct 2013
Main final analysis from AZURE trial
Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK
Main final analysis from AZURE trial ( Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK )
31 Oct 2013
Update on Anglo-Celtic Collaborative Oncology Group with overview of recent brea...
Prof Robert Leonard - Imperial College, London
Update on Anglo-Celtic Collaborative Oncology Group with overview of recent breast cancer trials ( Prof Robert Leonard - Imperial College, London )
23 Oct 2013
Brain mestastases from lung cancer ECC 2013
Dr Lucio Crinò - University Hospital of Perugia, Italy
Brain mestastases from lung cancer ECC 2013 ( Dr Lucio Crinò - University Hospital of Perugia, Italy )
23 Oct 2013
Where next in renal cell cancer with targeted therapies?
Dr Thomas Powles, Dr Victoria Galvis, Dr Marc Matrana, Prof John Wagstaff
Where next in renal cell cancer with targeted therapies? ( Dr Thomas Powles, Dr Victoria Galvis, Dr Marc Matrana, Prof John Wagstaff )
23 Oct 2013
Real-world data with pazopanib confirm clinical trial findings in renal cell can...
Dr Thomas Powles, Dr Victoria Galvis, Dr Marc Matrana , Prof John Wagstaff
Real-world data with pazopanib confirm clinical trial findings in renal cell cancer ( Dr Thomas Powles, Dr Victoria Galvis, Dr Marc Matrana , Prof John Wagstaff )
23 Oct 2013
European Cancer Congress 2013 - News Roundup
Prof Gordon Mcvie - ecancer Managing Editor and the European Institute of Oncolo...
European Cancer Congress 2013 - News Roundup ( Prof Gordon Mcvie - ecancer Managing Editor and the European Institute of Oncology )
22 Oct 2013
Treating chest lymph nodes in early breast cancer improves survival without Incr...
Dr Philip Poortmans - Institute Verbeeten, Tilburg, The Netherlands
Treating chest lymph nodes in early breast cancer improves survival without Increasing side effects ( Dr Philip Poortmans - Institute Verbeeten, Tilburg, The Netherlands )
18 Oct 2013
Evaluation of FIRE3 trial and ASPECT study in mCRC; implications in Japan
Dr Kei Muro - Aichi Cancer Center Hospital, Nagoya, Japan
Evaluation of FIRE3 trial and ASPECT study in mCRC; implications in Japan ( Dr Kei Muro - Aichi Cancer Center Hospital, Nagoya, Japan )
7 Oct 2013
FIRE-3 trial: Analysis of KRAS/NRAS and BRAF mutations and the potential for bio...
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Centre, Los Angeles, USA
FIRE-3 trial: Analysis of KRAS/NRAS and BRAF mutations and the potential for biomarkers ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Centre, Los Angeles, USA )
7 Oct 2013
Launch of the Institute of Cancer Policy
Prof Richard Sullivan - King's College London, UK
Launch of the Institute of Cancer Policy ( Prof Richard Sullivan - King's College London, UK )
7 Oct 2013
Stem cell therapy for prevention of radiation-induced salivary gland toxicity
Dr Rob Coppes - University of Groningen, Netherlands
Stem cell therapy for prevention of radiation-induced salivary gland toxicity ( Dr Rob Coppes - University of Groningen, Netherlands )
7 Oct 2013
Survival analysis of a follow-up phase III study of ipilimumab and dacarbazine i...
Dr Michele Maio - University Hospital of Siena, Siena, Italy
Survival analysis of a follow-up phase III study of ipilimumab and dacarbazine in metastatic melanoma ( Dr Michele Maio - University Hospital of Siena, Siena, Italy )
4 Oct 2013
Communicating with cancer patients
Prof John Smyth - Edinburgh University, UK
Communicating with cancer patients ( Prof John Smyth - Edinburgh University, UK )
4 Oct 2013
Development of bio-similar drugs
Dr Javier Cortés - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Development of bio-similar drugs ( Dr Javier Cortés - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
4 Oct 2013
Molecular biology guiding treatment of gastrointestinal stromal tumours (GISTs)
Dr Javier Martin-Broto - Son Espases Hospital, Palme de Mallorca, Spain
Molecular biology guiding treatment of gastrointestinal stromal tumours (GISTs) ( Dr Javier Martin-Broto - Son Espases Hospital, Palme de Mallorca, Spain )
4 Oct 2013
Percutaneous Hepatic Perfusion: localised chemo for liver cancer
Dr Alex Vahrmeijer - Leiden University Medical Centre, Netherlands
Percutaneous Hepatic Perfusion: localised chemo for liver cancer ( Dr Alex Vahrmeijer - Leiden University Medical Centre, Netherlands )
4 Oct 2013
Overview of major cancer policy research at ECC 2013
Prof Richard Sullivan - King's College London, UK
Overview of major cancer policy research at ECC 2013 ( Prof Richard Sullivan - King's College London, UK )
4 Oct 2013
Opportunity for mobile treatment setting for lymphoedema patients
Rachel Iredale - Tenovus, Cardiff, Wales, UK
Opportunity for mobile treatment setting for lymphoedema patients ( Rachel Iredale - Tenovus, Cardiff, Wales, UK )
3 Oct 2013
Comparing the PLCO and ERSPC trials on efficacy of prostate cancer screening
Prof Jack Cuzick - Wolfson Institute of Preventive Medicine, London, UK
Comparing the PLCO and ERSPC trials on efficacy of prostate cancer screening ( Prof Jack Cuzick - Wolfson Institute of Preventive Medicine, London, UK )
3 Oct 2013
The State of Oncology 2013
Prof Peter Boyle - International Prevention Research Institute, Lyon, France
The State of Oncology 2013 ( Prof Peter Boyle - International Prevention Research Institute, Lyon, France )
3 Oct 2013
Lgr5 stem cells in self-renewal and cancer
Dr Hans Clevers - Hubrecht Institute, Utrecht, Netherlands
Lgr5 stem cells in self-renewal and cancer ( Dr Hans Clevers - Hubrecht Institute, Utrecht, Netherlands )
3 Oct 2013
Importance of the minimum data set in cancer nursing
Alessandra Milani - European Institute of Oncology, Milan, Italy
Importance of the minimum data set in cancer nursing ( Alessandra Milani - European Institute of Oncology, Milan, Italy )
3 Oct 2013
The effects of communication technology on patients
Jana Pelouchova - European Cancer Patient Coalition
The effects of communication technology on patients ( Jana Pelouchova - European Cancer Patient Coalition )
3 Oct 2013
Analysis of progression free survival versus overall survival in melanoma
Dr Keith Flaherty - Dana-Farber Cancer Institute, Boston, USA
Analysis of progression free survival versus overall survival in melanoma ( Dr Keith Flaherty - Dana-Farber Cancer Institute, Boston, USA )
3 Oct 2013
New antibody drug, MPDL3280A, in non-small cell lung cancer
Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France
New antibody drug, MPDL3280A, in non-small cell lung cancer ( Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France )
3 Oct 2013
Prevention benefit from vitamin D
Prof Jack Cuzick - Wolfson Institute of Preventive Medicine, London, UK
Prevention benefit from vitamin D ( Prof Jack Cuzick - Wolfson Institute of Preventive Medicine, London, UK )
3 Oct 2013
Meta-analysis of ipilimumab in metastatic or locally advanced, unresectable mela...
Prof Dirk Schadendorf - Universitätsklinikum Essen, Essen, Germany
Meta-analysis of ipilimumab in metastatic or locally advanced, unresectable melanoma ( Prof Dirk Schadendorf - Universitätsklinikum Essen, Essen, Germany )
3 Oct 2013
Advances in patient management through web and mobile based applications
Dr Yvonne Wengstrom - Karolinska Institute, Stockholm, Sweden
Advances in patient management through web and mobile based applications ( Dr Yvonne Wengstrom - Karolinska Institute, Stockholm, Sweden )
3 Oct 2013
Standardised and centralised care of sarcomas
Prof Ian Judson - Institute of Cancer Research, London, UK
Standardised and centralised care of sarcomas ( Prof Ian Judson - Institute of Cancer Research, London, UK )
3 Oct 2013
Biomarkers in the BOLERO3 trial
Prof Guy Jerusalem - Centre Hospitalier Universitaire du Sart-Tilman, Liège, Bel...
Biomarkers in the BOLERO3 trial ( Prof Guy Jerusalem - Centre Hospitalier Universitaire du Sart-Tilman, Liège, Belgium )
3 Oct 2013
FLIMS workshop: Methods in clinical cancer research
Dr Piotr Rutkowski - Maria Sklodowska-Curie Memorial Cancer Center and Institut...
FLIMS workshop: Methods in clinical cancer research ( Dr Piotr Rutkowski -  Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland )
3 Oct 2013
Androgen blockade and ipilimumab against castration resistant prostate cancer
Dr Karim Fizazi - Institute Gustave Roussy, Paris, France
Androgen blockade and ipilimumab against castration resistant prostate cancer ( Dr Karim Fizazi - Institute Gustave Roussy, Paris, France )
3 Oct 2013
Observational RASTER study on the 70-gene-signature
Dr Caroline Drukker - Netherlands Cancer Institute, Amsterdam
Observational RASTER study on the 70-gene-signature ( Dr Caroline Drukker - Netherlands Cancer Institute, Amsterdam )
3 Oct 2013
Nursing highlights from ECC 2013
Dr Rosario Caruso - Università degli Studi di Milano, Milan, Italy
Nursing highlights from ECC 2013 ( Dr Rosario Caruso - Università degli Studi di Milano, Milan, Italy )
2 Oct 2013
The 'Make Sense Campaign' for head and neck cancer awareness
Prof René Leemans - General Secretary of the European Head and Neck Society
The 'Make Sense Campaign' for head and neck cancer awareness ( Prof René Leemans - General Secretary of the European Head and Neck Society )
2 Oct 2013
TDM1 versus physicians choice in treatment in breast cancer
Dr Hans Wildiers - University Hospital Gasthuisberg, Belgium
TDM1 versus physicians choice in treatment in breast cancer ( Dr Hans Wildiers - University Hospital Gasthuisberg, Belgium )
30 Sep 2013
The State of Oncology 2013: a new report draws attention on disparities in cance...
Prof Peter Boyle - International Prevention Research Institute
The State of Oncology 2013: a new report draws attention on disparities in cancer care ( Prof Peter Boyle - International Prevention Research Institute )
30 Sep 2013
Aspirin may act on blood platelets to improve survival in colon cancer patients
Dr Marlies Reimers - Leiden University Medical Center, Netherlands
Aspirin may act on blood platelets to improve survival in colon cancer patients ( Dr Marlies Reimers - Leiden University Medical Center, Netherlands )
30 Sep 2013
Comment on prostate cancer screening from the ECC 2013 Scientific Co-Chair
Prof Cora Sternberg - San Camillo and Forlanini Hospitals, Rome, Italy
Comment on prostate cancer screening from the ECC 2013 Scientific Co-Chair ( Prof Cora Sternberg - San Camillo and Forlanini Hospitals, Rome, Italy )
30 Sep 2013
Phase III trial, ICON6, shows cediranib improves survival in recurrent ovarian c...
Prof Jonathan Ledermann - UCL Cancer Institute, University College London, UK
Phase III trial, ICON6, shows cediranib improves survival in recurrent ovarian cancer ( Prof Jonathan Ledermann - UCL Cancer Institute, University College London, UK )
30 Sep 2013
Comment on primary site tumours from the ECC 2013 Scientific Co-Chair
Prof Cora Sternberg - San Camillo and Forlanini Hospitals, Rome, Italy
Comment on primary site tumours from the ECC 2013 Scientific Co-Chair ( Prof Cora Sternberg - San Camillo and Forlanini Hospitals, Rome, Italy )
30 Sep 2013
Research shows how aspirin may act on blood platelets to improve survival in col...
Dr Marlies Reimers - Leiden University Medical Center, Netherlands
Research shows how aspirin may act on blood platelets to improve survival in colon cancer patients ( Dr Marlies Reimers - Leiden University Medical Center, Netherlands )
30 Sep 2013
ICON6 phase III trial shows cediranib improves survival in recurrent ovarian can...
Prof Jonathan Ledermann - UCL Cancer Institute, University College London, UK
ICON6 phase III trial shows cediranib improves survival in recurrent ovarian cancer ( Prof Jonathan Ledermann - UCL Cancer Institute, University College London, UK )
30 Sep 2013
Comment on immunotherapy in lung cancer from the ECC 2013 Scientific Co-Chair
Prof Cora Sternberg - San Camillo and Forlanini Hospitals, Rome, Italy
Comment on immunotherapy in lung cancer from the ECC 2013 Scientific Co-Chair ( Prof Cora Sternberg - San Camillo and Forlanini Hospitals, Rome, Italy )
29 Sep 2013
Identifying disease-causing mechanisms in cancers with unknown primary site impr...
Dr Zoran Gatalica - Caris Life Sciences, Phoenix, USA
Identifying disease-causing mechanisms in cancers with unknown primary site improves treatment and survival ( Dr Zoran Gatalica - Caris Life Sciences, Phoenix, USA )
29 Sep 2013
Prostate-specific antigen test 'does more harm than good'
Prof Mathieu Boniol - International Prevention Research Institute, Lyon, France
Prostate-specific antigen test 'does more harm than good' ( Prof Mathieu Boniol - International Prevention Research Institute, Lyon, France )
29 Sep 2013
Results for new antibody drug in non-small cell lung cancer
Prof Jean-Charles Soria - Institut Gustave Roussy, Villejuif, France
Results for new antibody drug in non-small cell lung cancer ( Prof Jean-Charles Soria - Institut Gustave Roussy, Villejuif, France )
29 Sep 2013
Prostate-specific antigen test 'does more harm than good'
Prof Mathieu Boniol - International Prevention Research Institute, Lyon, France
Prostate-specific antigen test 'does more harm than good' ( Prof Mathieu Boniol - International Prevention Research Institute, Lyon, France )
29 Sep 2013
Identifying disease-causing mechanisms in cancers with unknown primary site i
Dr Zoran Gatalica - Caris Life Sciences, Phoenix, USA
Identifying disease-causing mechanisms in cancers with unknown primary site i ( Dr Zoran Gatalica - Caris Life Sciences, Phoenix, USA )
29 Sep 2013
Impact of radiotherapy on loco-regional control
Prof Ian Kunkler - University of Edinburgh, UK
Impact of radiotherapy on loco-regional control ( Prof Ian Kunkler - University of Edinburgh, UK )
28 Sep 2013
Fall in colorectal cancer death rates attributed to screening
Prof Philippe Autier - International Prevention Research Institute, Lyon, France
Fall in colorectal cancer death rates attributed to screening ( Prof Philippe Autier - International Prevention Research Institute, Lyon, France )
28 Sep 2013
Diabetes linked to increased risk and poorer outcomes in breast and colon cancer
Dr Kirstin De Bruijn - Erasmus University Medical Center, Rotterdam, Netherlands
Diabetes linked to increased risk and poorer outcomes in breast and colon cancer ( Dr Kirstin De Bruijn - Erasmus University Medical Center, Rotterdam, Netherlands )
28 Sep 2013
Association between overall survival and government spending on cancer care
Dr Felipe Ades - Institut Jules Bordet, Brussels, Belgium
Association between overall survival and government spending on cancer care ( Dr Felipe Ades - Institut Jules Bordet, Brussels, Belgium )
28 Sep 2013
Cancer survival in Europe strongly associated with government spend on health ca...
Dr Felipe Ades - Institut Jules Bordet, Brussels, Belgium
Cancer survival in Europe strongly associated with government spend on health care ( Dr Felipe Ades - Institut Jules Bordet, Brussels, Belgium )
28 Sep 2013
Diabetes causes increased risk of developing and dying from breast and colon can...
Dr Kirstin De Bruijn - Erasmus University Medical Center, Rotterdam, Netherlands
Diabetes causes increased risk of developing and dying from breast and colon cancer ( Dr Kirstin De Bruijn - Erasmus University Medical Center, Rotterdam, Netherlands )
28 Sep 2013
Evidence that fall in colorectal cancer death rates is attributable to screening...
Prof Philippe Autier - International Prevention Research Institute, Lyon, France
Evidence that fall in colorectal cancer death rates is attributable to screening programmes ( Prof Philippe Autier - International Prevention Research Institute, Lyon, France )
28 Sep 2013
ECC 2013 Preview: Oncopolicy, personalised medicine and nursing sessions at ECC ...
Prof John Yarnold, Prof Cora Sternberg, Prof Cornelis van de Velde and Prof Mart...
ECC 2013 Preview: Oncopolicy, personalised medicine and nursing sessions at ECC 2013 ( Prof John Yarnold, Prof Cora Sternberg, Prof Cornelis van de Velde and Prof Martine Piccart )
11 Jul 2013
ECC 2013 Preview: Importance of multidisciplinarity at ECC 2013
Prof John Yarnold, Prof Cora Sternberg, Prof Cornelis van de Velde and Prof Mart...
ECC 2013 Preview: Importance of multidisciplinarity at ECC 2013 ( Prof John Yarnold, Prof Cora Sternberg, Prof Cornelis van de Velde and Prof Martine Piccart )
11 Jul 2013
ECC 2013 Preview: Expectations for ECC 2013
Prof Graeme Poston, Prof Vincenzo Valentini and Ian Banks
ECC 2013 Preview: Expectations for ECC 2013 ( Prof Graeme Poston, Prof Vincenzo Valentini and Ian Banks )
11 Jul 2013
ECC 2013 Preview: Scientific programme highlights
Prof Vincenzo Valentini and Ian Banks
ECC 2013 Preview: Scientific programme highlights ( Prof Vincenzo Valentini and Ian Banks )
11 Jul 2013
ECC 2013 Preview: Multidisciplinarity and the scientific programme
Prof Graeme Poston, Prof Vincenzo Valentini and Ian Banks
ECC 2013 Preview: Multidisciplinarity and the scientific programme ( Prof Graeme Poston, Prof Vincenzo Valentini and Ian Banks )
11 Jul 2013
ECC 2013 Preview: Surgical oncology and the 'Patient Track'
Prof Graeme Poston and Ian Banks
ECC 2013 Preview: Surgical oncology and the 'Patient Track' ( Prof Graeme Poston and Ian Banks )
11 Jul 2013